Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Waxman Plans Bill To Set Medicare Part D Drug Prices At Medicaid Level For Dual-eligibles

This article was originally published in The Pink Sheet Daily

Executive Summary

Bill comes on heels of House Oversight Committee report showing Part D plans pay on average 30 percent more for drugs compared to Medicaid.

You may also be interested in...



House Health Reform Bill Increases Drug Rebates, Drops Part D Donut Hole

The House health care reform bill asks pharmaceutical manufacturers to pay their share of the cost of expanding health care coverage by paying higher rebates on more drugs

House Health Reform Bill Increases Drug Rebates, Drops Part D Donut Hole

The House health care reform bill asks pharmaceutical manufacturers to pay their share of the cost of expanding health care coverage by paying higher rebates on more drugs

Medicaid Rebates For Part D Duals Would Jeopardize Program, Experts Say

Some Medicare Part D experts are warning of the unintended consequences that could result from applying Medicaid drug pricing policy to low-income seniors enrolled in Medicare Part D drug plans

Related Content

Topics

UsernamePublicRestriction

Register

PS068138

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel